Turn Therapeutics (TTRX) Total Debt (2025 - 2026)
Turn Therapeutics' quarterly Total Debt came in at $8.7 million in Q1 2026, up 187.41% quarter-over-quarter from $3.0 million in Q4 2025.
Turn Therapeutics has reported Total Debt for 2 years, with the latest figure at $8.7 million in Q1 2026.
- For the quarter ending Q1 2026, Total Debt changed N/A year-over-year to $8.7 million; the trailing twelve-month figure through Mar 2026 stood at $8.7 million (changed N/A YoY), and the FY2025 full-year result was $3.0 million, changed N/A from the prior year.
- Total Debt for Q1 2026 stood at $8.7 million, up from $3.0 million in the prior quarter.
- The five-year high for Total Debt was $8.7 million in Q1 2026, with the low at $3.0 million in Q4 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 319.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 110.96 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.99 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Turn Therapeutics | 188.06 Mn | 188.06 Mn | - | 8.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.70 Mn |
| Dec 31, 2025 | 3.03 Mn |